Contributors |
|
xi | |
Preface |
|
xiii | |
|
Chapter 1 The physics of dissolution Dynamic Nuclear Polarization |
|
|
1 | (28) |
|
|
|
1 | (1) |
|
1.2 Polarization, magnetization, sensitivity, and hyperpolarization |
|
|
2 | (4) |
|
1.3 Methods of hyperpolarization |
|
|
6 | (2) |
|
1.4 Dynamic Nuclear Polarization |
|
|
8 | (10) |
|
1.5 The DNP sample: formulation of the imaging agent and the electron paramagnetic agent |
|
|
18 | (3) |
|
1.6 Dissolution and relaxation |
|
|
21 | (2) |
|
|
23 | (6) |
|
|
24 | (5) |
|
Chapter 2 Hardware for preparing HP 13C-molecules: from polarizer to patient |
|
|
29 | (20) |
|
|
|
|
29 | (5) |
|
2.2 Monitoring of solid-state 13C polarization |
|
|
34 | (1) |
|
|
35 | (1) |
|
|
35 | (5) |
|
|
40 | (2) |
|
|
42 | (2) |
|
|
44 | (2) |
|
|
46 | (3) |
|
|
47 | (1) |
|
|
47 | (2) |
|
Chapter 3 HP acquisition methods: pulse sequences, reconstruction, and RF coils |
|
|
49 | (26) |
|
|
|
|
49 | (1) |
|
3.2 Hyperpolarized imaging considerations |
|
|
50 | (5) |
|
3.3 Pulse sequences and reconstruction |
|
|
55 | (9) |
|
|
64 | (4) |
|
|
68 | (7) |
|
|
69 | (6) |
|
Chapter 4 HP experimental methods: cells and animals |
|
|
75 | (18) |
|
|
|
75 | (1) |
|
4.2 Dissolution--What is in it? |
|
|
76 | (1) |
|
4.3 Transfer to the magnet--how fast can you run? |
|
|
77 | (1) |
|
4.4 Delivery--how much and how to? |
|
|
78 | (1) |
|
4.5 Preclinical model systems for testing of hyperpolarized 13C agents |
|
|
79 | (8) |
|
4.6 Understanding and interpreting the hyperpolarized signals to shed light on the underlying biochemistry of the pathology |
|
|
87 | (6) |
|
|
88 | (1) |
|
|
88 | (3) |
|
|
91 | (2) |
|
Chapter 5 HP agents and biochemical interactions |
|
|
93 | (36) |
|
|
|
93 | (2) |
|
5.2 Overview of biological HP agents |
|
|
95 | (10) |
|
5.3 Formulation of HP 13C agents for dissolution DNP |
|
|
105 | (5) |
|
5.4 Biochemical interactions of HP 13C agents |
|
|
110 | (6) |
|
5.5 Summary and conclusion |
|
|
116 | (13) |
|
|
118 | (11) |
|
Chapter 6 Analysis and visualization of hyperpolarized 13C MR data |
|
|
129 | (28) |
|
|
|
|
129 | (1) |
|
|
130 | (1) |
|
|
131 | (15) |
|
|
146 | (3) |
|
6.5 Evaluation of metabolism metrics |
|
|
149 | (4) |
|
|
153 | (4) |
|
|
153 | (4) |
|
Chapter 7 Integration into cancer studies |
|
|
157 | (30) |
|
|
7.1 Metabolic reprogramming is a central hallmark of cancer |
|
|
157 | (2) |
|
7.2 Metabolic reprogramming can be monitored to provide precision imaging of cancer |
|
|
159 | (1) |
|
7.3 Imaging oncogenic reprogramming of metabolism using HP 13C MRS/I in preclinical cancer models |
|
|
160 | (14) |
|
7.4 Imaging oncogenic reprogramming of metabolism using HP 13C MRS/I in the clinic |
|
|
174 | (3) |
|
|
177 | (10) |
|
|
177 | (1) |
|
|
177 | (10) |
|
Chapter 8 Neurological applications of hyperpolarized 13C MR |
|
|
187 | (30) |
|
|
8.1 Introduction: an overview of the brain and its metabolism |
|
|
187 | (2) |
|
8.2 Neurological applications of HP [ 1-13C]pyruvate |
|
|
189 | (10) |
|
8.3 New HP probes for brain applications |
|
|
199 | (5) |
|
8.4 Correlation studies for HP 13C data |
|
|
204 | (6) |
|
|
210 | (7) |
|
|
211 | (6) |
|
Chapter 9 Hyperpolarized MR in cardiology: probing the heart of life |
|
|
217 | (40) |
|
|
|
|
9.1 Fueling the pump: metabolism and the healthy heart |
|
|
217 | (13) |
|
9.2 Quantifying cardiac metabolism with MR |
|
|
230 | (10) |
|
9.3 Imaging hyperpolarized metabolism in the heart |
|
|
240 | (6) |
|
|
246 | (11) |
|
|
247 | (10) |
|
Chapter 10 Integration of Hyperpolarized 13C MRI into Liver Studies |
|
|
257 | (16) |
|
|
|
10.1 Liver imaging: state of the art |
|
|
257 | (1) |
|
10.2 Technical challenges of liver HP 13C MRI |
|
|
258 | (2) |
|
10.3 Liver metabolic pathways accessible via HP imaging |
|
|
260 | (2) |
|
10.4 Target applications of liver HP 13C MRI |
|
|
262 | (6) |
|
|
268 | (5) |
|
|
268 | (5) |
Index |
|
273 | |